Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ARWR Relative to the S&P 500

ARWR Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Arrowhead Pharmaceuticals, Inc. (NASD:ARWR) seasonal charts above shows that a Buy Date of June 13 and a Sell Date of September 21 has resulted in a geometric average return of 5.16% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 13 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 12.71% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

To download ARWR seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ARWR